Cargando…

Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment

Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR‐TKI tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Haixia, Yu, Shaorong, Chen, Dan, Jing, Changwen, Wang, Zhuo, Ma, Rong, Liu, Siwen, Ni, Jie, Feng, Jifeng, Wu, Jianzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221460/ https://www.ncbi.nlm.nih.gov/pubmed/28097086 http://dx.doi.org/10.1002/2211-5463.12147

Ejemplares similares

LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation
por: Liu, Siwen, et al.
Publicado: (2018)

Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro
por: Lou, Rui, et al.
Publicado: (2019)

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
por: Ni, Jie, et al.
Publicado: (2018)

Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells
por: Rough, James J, et al.
Publicado: (2010)

Exosomes: Decreased Sensitivity of Lung Cancer A549 Cells to Cisplatin
por: Xiao, Xia, et al.
Publicado: (2014)

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
por: Hu, Yong, et al.
Publicado: (2017)

miR-33 inhibition attenuates the effect of liver X receptor agonist T0901317 on expression of liver X receptor alpha in mice liver
por: Mohammadi, Abbas, et al.
Publicado: (2017)

Nedaplatin reduces multidrug resistance of non-small cell lung cancer by downregulating the expression of long non-coding RNA MVIH
por: Jing, Changwen, et al.
Publicado: (2020)

Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis
por: Liu, Yun, et al.
Publicado: (2015)

MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells
por: Jing, Changwen, et al.
Publicado: (2019)

Hemistepsin A inhibits T0901317-induced lipogenesis in the liver
por: Kim, Jae Kwang, et al.
Publicado: (2021)

Cancer-associated changes of emotional brain network in non-nervous system metastatic non-small cell lung cancer patients: a structural connectomic diffusion tensor imaging study
por: Liu, Siwen, et al.
Publicado: (2020)

The somatic mutation landscape of Chinese Colorectal Cancer
por: Ma, Rong, et al.
Publicado: (2020)

The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells induced by polyhexamethylene guanidine through inhibition of the NFκB signaling pathway
por: Wei, Lutang, et al.
Publicado: (2021)

Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis
por: Jing, Changwen, et al.
Publicado: (2019)

Comparative analysis of microRNA expression profiles between A549, A549/DDP and their respective exosomes
por: Qin, Xiaobing, et al.
Publicado: (2017)

Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer
por: Jing, Changwen, et al.
Publicado: (2018)

Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer
por: Chen, Dan, et al.
Publicado: (2018)

A Liver-X-Receptor Ligand, T0901317, Attenuates IgE Production and Airway Remodeling in Chronic Asthma Model of Mice
por: Shi, Ying, et al.
Publicado: (2014)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

CLASRP oncogene as a novel target for colorectal cancer
por: Gu, Quan, et al.
Publicado: (2023)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF (V600E) mutation in papillary thyroid carcinoma
por: Wang, Zhuo, et al.
Publicado: (2019)

Serum Platelet-Derived Growth Factor Is Significantly Lower in Patients with Lung Cancer and Continued to Decrease After Platinum-Based Chemotherapy
por: Ma, Rong, et al.
Publicado: (2020)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

EGFR-TKI不良反应管理专家共识
Publicado: (2019)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
por: Long, Jianlin, et al.
Publicado: (2022)

Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
por: Liu, Rong, et al.
Publicado: (2022)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway
por: Wang, Lihui, et al.
Publicado: (2018)

T0901317, an Agonist of Liver X Receptors, Attenuates Neuronal Apoptosis in Early Brain Injury after Subarachnoid Hemorrhage in Rats via Liver X Receptors/Interferon Regulatory Factor/P53 Upregulated Modulator of Apoptosis/Dynamin-1-Like Protein Pathway
por: Dai, Jiaxing, et al.
Publicado: (2021)

Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer
por: Ma, Rong, et al.
Publicado: (2017)

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
por: Chen, Yi, et al.
Publicado: (2023)

Monoclonal antibody AC10364 inhibits cell proliferation in 5-fluorouracil resistant hepatocellular carcinoma via apoptotic pathways
por: Wu, Jianzhong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4ukm5hv8d4a4io988tfh76mhnm